| scholarly article | Q13442814 |
| P50 | author | Michael Pfreundschuh | Q1928879 |
| P2093 | author name string | Norbert Schmitz | |
| Markus Loeffler | |||
| Alfred C Feller | |||
| Dirk Hasenclever | |||
| Lorenz Trümper | |||
| Christian Rübe | |||
| Marcel Reiser | |||
| Dieter K Hossfeld | |||
| Christian Rudolph | |||
| Hartmut Eimermacher | |||
| Rudolf Schmits | |||
| German High-Grade Non-Hodgkin's Lymphoma Study Group | |||
| Marita Kloess | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| etoposide | Q418817 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 634-641 | |
| P577 | publication date | 2004-03-11 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. | |
| P478 | volume | 104 |
| Q37229557 | 25 Years Old Women With Inflammatory Low Back Pain |
| Q35930640 | A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. |
| Q50561543 | A Mathematical Model of Granulopoiesis Incorporating the Negative Feedback Dynamics and Kinetics of G-CSF/Neutrophil Binding and Internalization. |
| Q37956318 | A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma |
| Q95831565 | A biomathematical model of human erythropoiesis and iron metabolism |
| Q34766672 | A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration |
| Q41513921 | A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry |
| Q33712928 | A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment |
| Q46308723 | A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma |
| Q34065271 | A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug |
| Q100940737 | A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise |
| Q52923724 | A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. |
| Q46916880 | A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203. |
| Q40219989 | A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma |
| Q46606526 | A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma |
| Q38838789 | A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma |
| Q35086595 | A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial |
| Q35551019 | A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma |
| Q44048667 | A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. |
| Q43109507 | A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? |
| Q92119272 | A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma |
| Q89618740 | A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas |
| Q38465823 | A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas |
| Q37588583 | A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma |
| Q44435533 | Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). |
| Q35208183 | Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. |
| Q53576374 | Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. |
| Q40597967 | Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma |
| Q38609747 | Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. |
| Q38798801 | Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas |
| Q40757934 | Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma |
| Q38212694 | Appropriate management of molecular subtypes of diffuse large B-cell lymphoma |
| Q43087932 | Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. |
| Q51672210 | Asymptomatic C-reactive protein elevation in neutropenic children. |
| Q56985985 | Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial |
| Q36623644 | Autologous stem cell transplantation beyond 60 years of age. |
| Q51823817 | Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. |
| Q40834336 | Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas |
| Q51161466 | Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. |
| Q35673260 | Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy |
| Q58088141 | Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies |
| Q38528166 | Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission |
| Q40342442 | Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. |
| Q44511075 | CHOP intensification: not yet state of the art. |
| Q41246604 | CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin |
| Q34566901 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group |
| Q43405855 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group |
| Q35638549 | CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials |
| Q46709432 | CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). |
| Q36485208 | Canadian supportive care recommendations for the management of neutropenia in patients with cancer |
| Q80964885 | Cancer and ageing: a nexus at several levels |
| Q90066133 | Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis |
| Q40757884 | Case studies of elderly patients with non-Hodgkin's lymphoma. |
| Q51014998 | Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. |
| Q36262219 | Central nervous system-directed preventative therapy in adults with lymphoma |
| Q45160611 | Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines |
| Q35998006 | Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma |
| Q38121735 | Chemotherapy dosing in overweight and obese patients with cancer |
| Q93162455 | Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study |
| Q36450307 | Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma. |
| Q37602388 | Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma |
| Q33438039 | Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group |
| Q47918300 | Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma |
| Q64108350 | Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis |
| Q39141802 | Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries |
| Q45252389 | Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands |
| Q40757980 | Current approaches to the treatment of non-Hodgkin's lymphoma |
| Q26770385 | Current challenges and novel treatment strategies in double hit lymphomas |
| Q37132898 | Current treatment approaches for diffuse large B-cell lymphoma |
| Q35536636 | Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. |
| Q30235296 | Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives |
| Q79711344 | Diffuse large B-cell lymphoma |
| Q37997054 | Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy? |
| Q46427411 | Do six or eight cycles work better with CHOP-14 and rituximab? |
| Q80601752 | Dose dance in lymphomas |
| Q57044605 | Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial |
| Q40459857 | Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. |
| Q46902513 | Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. |
| Q50492479 | Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. |
| Q46715682 | Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma |
| Q51764521 | EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. |
| Q57494293 | Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience |
| Q36443643 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer |
| Q35483564 | Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma |
| Q37300030 | Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma |
| Q37771248 | Expanded use of rituximab in the management of non-Hodgkin lymphoma. |
| Q48232545 | Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. |
| Q42547376 | First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions |
| Q40163155 | Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. |
| Q45157056 | Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients w |
| Q53133078 | Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. |
| Q37784673 | Front-line management of diffuse large B cell lymphoma |
| Q37136999 | Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. |
| Q26800954 | G-CSF and GM-CSF in Neutropenia |
| Q24240753 | Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma |
| Q33417812 | Growth factor use in medication-induced hematologic toxicity |
| Q54708579 | Guidelines for the management of diffuse large B-cell lymphoma. |
| Q47878810 | Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. |
| Q33375173 | High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. |
| Q43109656 | High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone |
| Q58908211 | High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data |
| Q24242089 | High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults |
| Q33626490 | High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma |
| Q60339417 | High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma |
| Q38036587 | Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity |
| Q92540102 | Hypercalcemia in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: An Unusual Presentation of a Rare Disease and Literature Review |
| Q35004750 | Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points |
| Q38802896 | Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. |
| Q40675622 | Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. |
| Q41361615 | Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study |
| Q37547188 | Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care |
| Q33585882 | Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia |
| Q104795127 | Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden |
| Q89635392 | Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology |
| Q40338112 | Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. |
| Q43265563 | Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody |
| Q26849243 | Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics |
| Q53203745 | Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. |
| Q46425557 | Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma |
| Q43208429 | Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience |
| Q44660914 | Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. |
| Q37406798 | Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials |
| Q33330490 | MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians |
| Q38147318 | MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas |
| Q40253260 | Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. |
| Q36949798 | Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma |
| Q37625441 | Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q37738501 | Management of advanced-stage peripheral T-cell lymphomas |
| Q38345599 | Management of diffuse large B-cell lymphoma (DLBCL). |
| Q35987747 | Management of muscle-invasive bladder cancer in the elderly |
| Q36524619 | Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma |
| Q35030415 | Merging concepts - coupling an agent-based model of hematopoietic stem cells with an ODE model of granulopoiesis |
| Q82323531 | Meta-Analysis of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy |
| Q40426672 | Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis |
| Q46951026 | Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia |
| Q47657705 | Model-based optimization of G-CSF treatment during cytotoxic chemotherapy |
| Q51029245 | Modeling cancer-immune responses to therapy. |
| Q38932141 | Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma |
| Q64058452 | Modeling individual time courses of thrombopoiesis during multi-cyclic chemotherapy |
| Q34996295 | Modelling chemotherapy effects on granulopoiesis |
| Q51981581 | Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. |
| Q41957184 | Modelling lymphoma therapy and outcome |
| Q42165704 | Monoclonal antibody treatment of malignant lymphoma |
| Q81643454 | Moving beyond febrile neutropenia |
| Q38179500 | Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma |
| Q34269228 | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma |
| Q33372559 | Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma |
| Q38731955 | Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns and Outcomes in Very Elderly Patients with Diffuse Large B-cell Lymphoma: The Korean Cancer Study Group LY16-01. |
| Q33446735 | NHL (diffuse large B cell lymphoma) |
| Q33846734 | NHL (diffuse large B-cell lymphoma). |
| Q38228214 | Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer |
| Q80900054 | Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study |
| Q37786616 | New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma |
| Q37807160 | New drugs for aggressive B-cell and T-cell lymphomas |
| Q39027859 | Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. |
| Q43139321 | Non-Hodgkin's lymphoma in the elderly |
| Q36429727 | Novel treatment strategies for aggressive non-Hodgkin's lymphoma |
| Q55282730 | Nuances in the Management of Aggressive Lymphomas. |
| Q53088479 | Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. |
| Q83833400 | Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14) |
| Q48726057 | Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. |
| Q42921293 | PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma |
| Q36786000 | Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma |
| Q33632239 | Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials |
| Q36297208 | Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia |
| Q79603527 | Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma |
| Q83234535 | Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis |
| Q53588155 | Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. |
| Q36327074 | Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action |
| Q36677460 | Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia |
| Q36235531 | Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy |
| Q38225700 | Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review |
| Q36427261 | Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans |
| Q37731964 | Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma |
| Q36360736 | Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. |
| Q46658574 | Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma |
| Q45933150 | Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. |
| Q85804046 | Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype |
| Q35091598 | Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study |
| Q37935990 | Prevention of CNS relapse in diffuse large B-cell lymphoma |
| Q41170489 | Primary Central Nervous System Anaplastic Large T-cell Lymphoma |
| Q36237659 | Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. |
| Q41029436 | Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group |
| Q56784798 | Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G |
| Q46130198 | Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab |
| Q35613669 | Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis |
| Q33756369 | Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? |
| Q48706314 | Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily |
| Q39314640 | R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care? |
| Q53229025 | R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. |
| Q46600594 | R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy |
| Q89037605 | R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial |
| Q43914821 | Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network |
| Q34062432 | Recent advances in the treatment of B-cell lymphoma |
| Q47131247 | Recent advances in understanding and managing T-cell lymphoma |
| Q89777500 | Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma |
| Q36411719 | Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease |
| Q36167592 | Repopulation of cancer cells during therapy: an important cause of treatment failure |
| Q43441516 | Respiratory status deterioration during G-CSF-induced neutropenia recovery |
| Q36417808 | Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) |
| Q33612733 | Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies |
| Q36836092 | Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma |
| Q34611337 | Risks and consequences of chemotherapy-induced neutropenia |
| Q37508007 | Rituximab and chemotherapy in diffuse large B-cell lymphoma |
| Q36573823 | Rituximab for the treatment of diffuse large B-cell lymphomas |
| Q33407265 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles |
| Q48229580 | Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. |
| Q84431165 | SEOM clinical guidelines for myeloid growth factors |
| Q51644203 | SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. |
| Q37579299 | Second-line treatment paradigms for diffuse large B-cell lymphomas |
| Q46586190 | Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy |
| Q36851424 | Senior adult oncology |
| Q87307378 | Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy |
| Q37473480 | Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the D |
| Q34742742 | Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). |
| Q37539436 | Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. |
| Q37809085 | Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas |
| Q81890149 | Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) |
| Q36529853 | Supportive therapy in medical therapy of head and neck tumors |
| Q30244553 | T-cell lymphomas, a challenging disease: types, treatments, and future. |
| Q47131982 | TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. |
| Q35989968 | Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. |
| Q37807310 | The Myeloid Growth Factors |
| Q35967278 | The colony-stimulating factors: use to prevent and treat neutropenia and its complications |
| Q28389285 | The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma |
| Q38614642 | The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study |
| Q51344608 | The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. |
| Q40220381 | The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study |
| Q34352408 | The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials |
| Q79536301 | The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma |
| Q38190105 | The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |
| Q38198754 | The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. |
| Q36210937 | The role of pixantrone in the treatment of non-Hodgkin's lymphoma |
| Q37810267 | Therapeutic approaches to non-Hodgkin’s lymphoma in the elderly patient |
| Q41890864 | Therapy Outcome of a T-Cell-Rich-B-Cell Lymphoma (TCRBCL) Patient with R-CHOP in Ibadan, Nigeria: a Case Report |
| Q43429634 | Therapy for diffuse large B-cell lymphoma: getting personal |
| Q43272427 | Therapy of diffuse large B-cell lymphomas |
| Q33670421 | Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma |
| Q50850396 | Treatment of Diffuse Large B-Cell Lymphoma. |
| Q38118167 | Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience |
| Q27006062 | Treatment of diffuse large B cell lymphoma |
| Q37244710 | Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes |
| Q37998553 | Treatment of the elderly patient with diffuse large B cell lymphoma |
| Q48517926 | Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma |
| Q56882990 | Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma |
| Q37705417 | Unresolved issues in diffuse large B-cell lymphomas |
| Q36269919 | Update on lymphoma management: diffuse large B-cell NHL. |
| Q36776444 | Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma |
| Q44580650 | WITHDRAWN: Addition of amifostine to CHOP regimen significantly reduced toxicity in patients with aggressive non-Hodgkin's lymphoma without affecting the long term survival: Results of a phase II trial |
| Q36095287 | Weight-based chemotherapy dosing in obese patients with cancer: back to the future |
| Q48123569 | Whom to treat? Factors associated with chemotherapy recommendations and outcomes among patients with NHL at the Uganda Cancer Institute. |
| Q52928040 | [Burkitt's and Burkitt-like lymphoma. Molecular definition and value of the World Health Organisation's diagnostic criteria]. |
| Q79955220 | [Treatment of aggressive lymphomas] |
| Q84618319 | [Treatment of aggressive non-Hodgkin's lymphomas] |
| Q81588936 | [Treatment of hematological malignancies with monoclonal antibodies] |
Search more.